Drug intelligence / Profile preview

HFB200902

Development stage: Discontinued
Lead developer: FibroGen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

HFB200902 is a preclinical, first-in-class anti–galectin-9 monoclonal antibody immunotherapy originally developed by HiFiBiO Therapeutics for the treatment of acute myeloid leukemia and solid tumors. It functions as a galectin-9 antagonist that neutralizes galectin-9 and blocks its interaction with the inhibitory receptors TIM3 and CD44, thereby preventing galectin-9–mediated immunosuppressive signaling in effector and regulatory T cells, inhibiting Th1 apoptosis and Treg expansion, and enhancing antitumor immune responses in preclinical tumor models, including in combination with PD-1 blockade.[1][3][5][7][9]

Targets

CD44 (CD44 antigen)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)LGALS9 (Galectin-9)

Beyond the preview

Go deeper on HFB200902.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HFB200902.

Explore the full profile